CELC — Celcuity LLC
NASDAQ · Healthcare · Biotechnology
$92.23
+$0.25 (+0.28%)
Celcuity LLC (CELC) is a biotechnology company listed on NASDAQ. It is led by Brian F. Sullivan, based in 2800 Campus Drive, Minneapolis, MN, United States, 55441, with about 155 employees. Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Net income was -$43.8M. CELC currently screens at market cap $4.33B.
Use this CELC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CELC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CELC SEC filings page. Lician reads the product cache first so this HTML stays unique to Celcuity LLC even when a live quote feed is slow.
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
CELC Key Statistics
Market Cap
$4.33B
Volume
655,397
Previous Close
$92.27
Day Range
$91.02 – $96.16
P/B Ratio
79.56
EPS
-$2.83
Revenue
$0.00
Net Income
-$111.78M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
155
CELC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$111.78M | -$63.78M | -$40.37M | -$29.61M |
| EPS (Diluted) | -$2.83 | -$2.69 | -$2.64 | $0.00 |
Total Assets
$245.12M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$22.51M
Operating Cash Flow
-$83.47M
Free Cash Flow
$0.00
Celcuity LLC Company Information
- Co-Founder, Chairman & CEO
- Brian F. Sullivan
- Headquarters
- 2800 Campus Drive, Minneapolis, MN, United States, 55441
- Website
- www.celcuity.com
- Phone
- (763) 392-0123
- IPO / Founded
- 2017-09-20
- Sector
- Healthcare
- Industry
- Biotechnology